NIDA-41020
Modify Date: 2025-08-25 16:58:17
NIDA-41020 structure
|
Common Name | NIDA-41020 | ||
|---|---|---|---|---|
| CAS Number | 502486-89-7 | Molecular Weight | 459.36800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H24Cl2N4O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of NIDA-41020NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a Ki of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET)[1]. |
| Name | 1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a Ki of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET)[1]. |
|---|---|
| Related Catalog | |
| Target |
CB1:4.1 nM (Ki) |
| References |
| Molecular Formula | C23H24Cl2N4O2 |
|---|---|
| Molecular Weight | 459.36800 |
| Exact Mass | 458.12800 |
| PSA | 59.39000 |
| LogP | 5.62260 |
| InChIKey | KWDBQJRWPWTGPF-UHFFFAOYSA-N |
| SMILES | COc1ccc(-c2c(C)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1 |
| Storage condition | 2-8°C |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H315-H319-H335 |
| Precautionary Statements | P261-P264-P301 + P310-P305 + P351 + P338 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Risk Phrases | 25-36/37/38 |
| Safety Phrases | 26-45 |
| RIDADR | UN 2811 6.1 / PGIII |
|
Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists
Drug Discov. Today 10 , 693-702, (2005) The proven clinical efficacy of the CB1 cannabinoid receptor antagonist rimonabant in obesity and its further therapeutic potential has given a tremendous impetus to the discovery of novel CB1 antagon... |
|
|
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
J. Med. Chem. 46 , 642-645, (2003) Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in... |
| 1-(2,4-Dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide |
| Roxindole hydrochloride |